Leader in Cardiovascular Innovation
Developing Treatments for Hypercholesterolemia and NAFLD/NASH
Ground-Breaking Products Development
With partnerships with various healthcare investors, we have spearheaded in-depth studies in cholesterol-lowering, oral drugs that can aid in the treatment of cardiometabolic diseases. Our company’s lead product candidate is CVI-LM001, which is currently at phase 2 proof-of-concept clinical development stage for the treatment of hypercholesterolemia. CVI-LM001 is a novel, first-in-class, safe, and oral once-daily PCSK9 modulator with a distinct mechanism of actions.